EHMT2 methyltransferase governs cell identity in the lung and is required for KRASG12D tumor development and propagation

  1. Ariel pribluda
  2. Anneleen Daemen
  3. Anthony Nelson Lima Mr.
  4. Xi Wang
  5. Marc Hafner
  6. Chungkee Poon
  7. Zora Modrusan
  8. Anand Kumar Katakam
  9. Oded Foreman
  10. Jefferey Eastham
  11. Jefferey Hung
  12. Benjamin Haley
  13. Julia T Garcia
  14. Erica L Jackson
  15. Melissa R Junttila  Is a corresponding author
  1. Surrozen, United States
  2. Oric Pharma, United States
  3. Genentech, Inc, United States
  4. Stanford University, United States
  5. Scorpion Therapeutics, United States

Abstract

Lung development, integrity and repair rely on precise Wnt signaling, which is corrupted in diverse diseases, including cancer. Here, we discover that EHMT2 methyltransferase regulates Wnt signaling in the lung by controlling the transcriptional activity of chromatin-bound β-catenin, through a non-histone substrate in mouse lung. Inhibition of EHMT2 induces transcriptional, morphologic, and molecular changes consistent with alveolar type 2 (AT2) lineage commitment. Mechanistically, EHMT2 activity functions to support regenerative properties of KrasG12D tumors and normal AT2 cells - the predominant cell of origin of this cancer. Consequently, EHMT2 inhibition prevents KrasG12D lung adenocarcinoma tumor formation and propagation and disrupts normal AT2 cell differentiation. Consistent with these findings, low gene EHMT2 expression in human lung adenocarcinoma correlates with enhanced AT2 gene expression and improved prognosis. These data reveal EHMT2 as a critical regulator of Wnt signaling, implicating Ehmt2 as a potential target in lung cancer and other AT2-mediated lung pathologies.

Data availability

Code and data availability All source code used in this study has been made available in the R computer language, in a fully documented software and data package. This package is freely available under the Creative Commons 3.0 license and can be downloaded from https://github.com/anneleendaemen/G9a.CellIdentity.Lung

The following previously published data sets were used

Article and author information

Author details

  1. Ariel pribluda

    Discovery Biology, Surrozen, South San Francisco, United States
    Competing interests
    Ariel pribluda, was an employee of Genentech when the work was performed and may hold stock..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2817-2827
  2. Anneleen Daemen

    Computational biology, Oric Pharma, South San Francisco, United States
    Competing interests
    Anneleen Daemen, was an employee of Genentech when the work was performed and may hold stock..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6287-7105
  3. Anthony Nelson Lima Mr.

    Department of Translational Oncology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Anthony Nelson Lima, holds shares in the company.
  4. Xi Wang

    Department of Translational Oncology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Xi Wang, holds shares in the company.
  5. Marc Hafner

    Department of Bioinformatics and Computational Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Marc Hafner, holds shares in the company.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1337-7598
  6. Chungkee Poon

    Department of Immunology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Chungkee Poon, holds shares in the company.
  7. Zora Modrusan

    Department of Molecular Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Zora Modrusan, holds shares in the company.
  8. Anand Kumar Katakam

    Department of Pathology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Anand Kumar Katakam, holds shares in the company.
  9. Oded Foreman

    Department of Pathology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Oded Foreman, holds shares in the company.
  10. Jefferey Eastham

    Department of Pathology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Jefferey Eastham, holds shares in the company.
  11. Jefferey Hung

    Department of Pathology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Jefferey Hung, holds shares in the company.
  12. Benjamin Haley

    Department of Molecular Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Benjamin Haley, holds shares in the company.
  13. Julia T Garcia

    Department of Genetics, Stanford University, Stanford, United States
    Competing interests
    Julia T Garcia, was an employee of Genentech when the work was performed and may hold stock..
  14. Erica L Jackson

    Scorpion Therapeutics, South San Francisco, United States
    Competing interests
    Erica L Jackson, was an employee of Genentech when the work was performed and may hold stock..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7100-8021
  15. Melissa R Junttila

    Biology, Oric Pharma, South San Francisco, United States
    For correspondence
    melissa.junttila@oricpharma.com
    Competing interests
    Melissa R Junttila, was an employee of Genentech when the work was performed and may hold stock..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3538-1192

Funding

The authors declare that there was no funding for this work.

Ethics

Animal experimentation: All animal studies were approved by the Institutional Animal Care and Use Committee at Genentech and adhere to the Guidelines for the Care and Use of Laboratory Animals (protocols 17-1217, 17-0107 and 18-1833 series).

Copyright

© 2022, pribluda et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,018
    views
  • 235
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ariel pribluda
  2. Anneleen Daemen
  3. Anthony Nelson Lima Mr.
  4. Xi Wang
  5. Marc Hafner
  6. Chungkee Poon
  7. Zora Modrusan
  8. Anand Kumar Katakam
  9. Oded Foreman
  10. Jefferey Eastham
  11. Jefferey Hung
  12. Benjamin Haley
  13. Julia T Garcia
  14. Erica L Jackson
  15. Melissa R Junttila
(2022)
EHMT2 methyltransferase governs cell identity in the lung and is required for KRASG12D tumor development and propagation
eLife 11:e57648.
https://doi.org/10.7554/eLife.57648

Share this article

https://doi.org/10.7554/eLife.57648

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark LaBarge
    Research Article

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Cancer Biology
    Jae Hun Shin, Jooyoung Park ... Alfred LM Bothwell
    Research Article

    Metastasis is the leading cause of cancer-related mortality. Paneth cells provide stem cell niche factors in homeostatic conditions, but the underlying mechanisms of cancer stem cell niche development are unclear. Here, we report that Dickkopf-2 (DKK2) is essential for the generation of cancer cells with Paneth cell properties during colon cancer metastasis. Splenic injection of Dkk2 knockout (KO) cancer organoids into C57BL/6 mice resulted in a significant reduction of liver metastases. Transcriptome analysis showed reduction of Paneth cell markers such as lysozymes in KO organoids. Single-cell RNA sequencing analyses of murine metastasized colon cancer cells and patient samples identified the presence of lysozyme positive cells with Paneth cell properties including enhanced glycolysis. Further analyses of transcriptome and chromatin accessibility suggested hepatocyte nuclear factor 4 alpha (HNF4A) as a downstream target of DKK2. Chromatin immunoprecipitation followed by sequencing analysis revealed that HNF4A binds to the promoter region of Sox9, a well-known transcription factor for Paneth cell differentiation. In the liver metastatic foci, DKK2 knockout rescued HNF4A protein levels followed by reduction of lysozyme positive cancer cells. Taken together, DKK2-mediated reduction of HNF4A protein promotes the generation of lysozyme positive cancer cells with Paneth cell properties in the metastasized colon cancers.